Oxidants induce alternative splicing of α-synuclein: Implications for Parkinson's disease

Free Radical Biology and Medicine

Volumn 48, Issue 3, 2010, Pages 377-383

  Kalivendi, Shasi V ^a   Yedlapudi, Deepthi ^a   Hillard, Cecilia J ^b   Kalyanaraman, B ^b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Alternative splicing; Dopamine neurons; MPTP; Neurotoxicity; Oxidative stress; Parkinson's disease; Synuclein

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; ALPHA SYNUCLEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEASOME; ROTENONE;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; EXON; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALE; MOUSE; NERVE CELL LESION; NERVE CELL NECROSIS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADRENERGIC AGENTS; ALPHA-SYNUCLEIN; ALTERNATIVE SPLICING; ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; HUMANS; IMMUNOBLOTTING; IMMUNOENZYME TECHNIQUES; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; NEURONS; OXIDANTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; ROTENONE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; UNCOUPLING AGENTS;

MUS;

EID: 73449099224     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2009.10.045     Document Type: Article

References (41)

1. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
2. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
3. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., and Masliah E. Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. Am. J. Pathol. 152 (1998) 367-372
4. Recchia A., Debetto P., Negro A., Guidolin D., Skaper S.D., and Giusti P. Alpha-synuclein and Parkinson's disease. FASEB J. 18 (2004) 617-626
5. Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology 58 (2002) 179-185
6. Chu Y., Dodiya H., Aebischer P., Olanow C.W., and Kordower J.H. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 3 (2009) 385-398
7. Fahan S., and Przedborski S. In: Rowland L.P. (Ed). Merritt's neurology (2000), Lippincott, Williams & Wilkins, New York 679-695
8. Hoglinger G.U., Carrard G., Michel P.P., Medja F., Lombes A., Ruberg M., Friguet B., and Hirsch E.C. Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem. 86 (2003) 1297-1307
9. Schmidt N., and Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural. Transm. 108 (2001) 1263-1282
10. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., and Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22 (2002) 7006-7015
11. Kalivendi S.V., Cunningham S., Kotamraju S., Joseph J., Hillard C.J., and Kalyanaraman B. Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide. J. Biol. Chem. 279 (2004) 15240-15247
12. Jenco J.M., Rawlingson A., Daniels B., and Morris A.J. Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleinsm. Biochemistry 37 (1998) 4901-4909
13. Payton J.E., Perrin R.J., Woods W.S., and George J.M. Structural determinants of PLD2 inhibition by alpha-synuclein. J. Mol. Biol. 337 (2004) 1001-1009
14. Lee F.J., Liu F., Pristupa Z.B., and Niznik H.B. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15 (2001) 916-926
15. Souza J.M., Giasson B.I., Lee V.M., and Ischiropoulos H. Chaperone-like activity of synucleins. FEBS Lett. 474 (2000) 116-119
16. Park S.M., Jung H.Y., Kim T.D., Park J.H., Yang C.H., and Kim J. Distinct roles of the N-terminal-binding domain and the C-terminal-solubilizing domain of alpha-synuclein, a molecular chaperone. J. Biol. Chem. 277 (2002) 28512-28520
17. Suh Y.H., and Checler F. Amyloid precursor protein, presenilins, and alpha-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol. Rev. 54 (2002) 469-525
18. Xia Y., Saitoh T., Ueda K., Tanaka S., Chen X., Hashimoto M., Hsu L., Conrad C., Sundsmo M., Yoshimoto M., et al. Characterization of the human alpha-synuclein gene: genomic structure, transcription start site, promoter region and polymorphisms. J. Alzheimers Dis. 3 (2001) 485-494
19. Hoyer W., Cherny D., Subramaniam V., and Jovin T.M. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43 (2004) 16233-16242
20. Kim T.D., Paik S.R., and Yang C.H. Structural and functional implications of C-terminal regions of alpha-synuclein. Biochemistry 41 (2002) 13782-13790
21. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jakala P., Hartmann T., Price D.L., et al. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2162-2167
22. Ueda K., Saitoh T., and Mori H. Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid. Biochem. Biophys. Res. Commun. 205 (1994) 1366-1372
23. Yoshimoto M., Iwai A., Kang D., Otero D.A., Xia Y., and Saitoh T. NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9141-9145
24. Cheung N.S., Hickling Y.M., and Beart P.M. Development and survival of rat embryonic mesencephalic dopaminergic neurones in serum-free, antioxidant-rich primary cultures. Neurosci. Lett. 233 (1997) 13-16
25. 2-induced transferrin receptor-dependent apoptosis in endothelial cells: role of ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10653-10658
26. Kalivendi S.V., Kotamraju S., Zhao H., Joseph J., and Kalyanaraman B. Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Effect of antiapoptotic antioxidants and calcium. J. Biol. Chem. 276 (2001) 47266-47276
27. McLean P.J., and Hyman B.T. An alternatively spliced form of rodent alpha-synuclein forms intracellular inclusions in vitro: role of the carboxy-terminus in alpha-synuclein aggregation. Neurosci. Lett. 323 (2002) 219-223
28. Betarbet R., Sherer T.B., and Greenmayre T. Ubiquitin-proteasome system and Parkinson's diseases. Exp. Neurol. 191 (2005) S17-S27
29. McNaught K.P., and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297 (2001) 191-194
30. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
31. Ischiropoulos H. Oxidative modifications of alpha-synuclein. Ann. N. Y. Acad. Sci. 991 (2003) 93-100
32. Dauer W., Kholodilov N., Vila M., Trillat A.C., Goodchild R., Larsen K.E., Staal R., Tieu K., Schmitz Y., Yuan C.A., et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14524-14529
33. Ischiropoulos H., and Beckman J.S. Oxidative stress and nitration in neurodegeneration: cause, effect, or association?. J. Clin. Invest. 111 (2003) 163-169
34. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., and Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4 (2002) 160-164
35. Iwata A., Maruyama M., Kanazawa I., and Nukina N. Alpha-synuclein affects the MAPK pathway and accelerates cell death. J. Biol. Chem. 276 (2001) 45320-45329
36. Hashimoto M., Takenouchi T., Rockenstein E., and Masliah E. Alpha-synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J. Neurochem. 85 (2003) 1468-1479
37. Matter N., Herrlich P., and Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420 (2002) 691-695
38. Weg-Remers S., Ponta H., Herrlich P., and Konig H. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 20 (2001) 4194-4203
39. Beyer K., Lao J.I., Carrato C., Mate J.L., Lopez D., Ferrer I., and Ariza A. Differential expression of alpha-synuclein isoforms in dementia with Lewy bodies. Neuropathol. Appl. Neurobiol. 30 (2004) 601-607
40. Sato N., Imaizumi K., Manabe T., Taniguchi M., Hitomi J., Katayama T., Yoneda T., Morihara T., Yasuda Y., Takagi T., et al. Increased production of beta-amyloid and vulnerability to endoplasmic reticulum stress by an aberrant spliced form of presenilin 2. J. Biol. Chem. 276 (2001) 2108-2114
41. Robertson J., Doroudchi M.M., Nguyen M.D., Durham H.D., Strong M.J., Shaw G., Julien J.P., and Mushynski W.E. A neurotoxic peripherin splice variant in a mouse model of ALS. J. Cell Biol. 160 (2003) 939-949